Viromed completes due diligence for planned relyon plasma acquisition, agrees key terms with TDK Electronics

• Viromed reached a non-binding understanding with TDK Electronics on key terms to buy relyon plasma, pending TDK corporate-body clearance.
• Due diligence has been completed; negotiations on the final share purchase agreement are slated for the coming weeks.
• Viromed is targeting swift conclusion of talks, followed by notarisation of the purchase agreement.
• relyon supplies modular plasma systems and OEM components; it also manufactures Viromed’s ViroCAP and PulmoPlas devices under an existing partnership.
• The deal would bring production in-house, tightening control of the value chain and supporting scaling while reducing reliance on external providers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viromed Medical AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2372196_en) on July 27, 2026, and is solely responsible for the information contained therein.